Jennifer Kaplan
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Biobank of small extracellular vesicles for pediatric sepsis
Open Date: 2023-08-17
Close Date: 2025-06-30
Grant: Close
Role of STAT3 in sepsis-induced adipose tissue browning and the impact of obesity
Open Date: 2017-09-25
Close Date: 2022-08-31
Grant: Close
PPAR gamma in pediatric sepsis and the inflammatory response in obesity
Open Date: 2010-06-01
Close Date: 2014-05-31
Articles (20)
Year:
2026
Objectives We sought to develop population pharmacokinetic (PopPK) models of total and free piperacillin in critically ill children and young adults. We investigated the impact of kidney function and injury biomarkers and the effect of time on pharmacokinetic (PK) parameters. Methods We enrolled patients admitted to a paediatric ICU and prescribed piperacillin/tazobactam. We collected residual blood from clinical samples for total and free piperacillin concentrations. PopPK models were developed using nonlinear mixed effects modelling. Specific covariates of interest included time after antibiotic initiation, using a 48 h threshold, and urine neutrophil gelatinase-associated lipocalin (uNGAL), a tubular injury biomarker. Monte Carlo simulations investigated target attainment using different dosing regimens. Results Total (n = 695) and free concentrations (n = 639) from 139 patients were best described by two-compartment models. Creatinine-based estimated glomerular filtration rate (eGFR), uNGAL, and time >48 h after initial dosing were significant covariates of both total and free piperacillin clearance. Regarding central volume, albumin and cumulative fluid balance were significant covariates on total and free piperacillin, respectively. Simulations showed a common regimen of 100 mg/kg piperacillin/tazobactam every 6 h over a 30 min infusion is only sufficient for targeting bacteria with MICs of 2 mg/L or less in patients >30 kg with eGFR <150 mL/min/1.73 m2 or <30 kg with eGFR <90 mL/min/1.73 m2. Conclusion Using a large sample of critically ill children, we developed total and free piperacillin population PK models and newly identified uNGAL and time as significant covariates on piperacillin clearance. These models may be used for model-informed precision dosing after external validation.
Year:
2026
Small extracellular vesicles (sEVs), typically <200 nm in diameter, have emerged as key mediators of intercellular communication, transferring bioactive molecules such as proteins, lipids, and nucleic acids between cells. This review focuses on the growing significance of sEVs in the context of sepsis, a life-threatening syndrome caused by a dysregulated immune response to infection. Sepsis remains a major global health challenge due to its complex pathophysiology, rapid progression, and the limitations of current diagnostic tools, which often fail to detect the condition early or accurately assess the host’s immune status. As interest grows in precision diagnostics, sEVs have gained attention for their potential as biomarkers in liquid biopsy—a minimally invasive approach that analyzes circulating vesicles to monitor disease. Small EVs reflect the physiological state of their cells of origin and can provide real-time insights into immune activation, inflammation, and pathogen presence. This review explores the mechanisms by which sEVs contribute to immune modulation in sepsis, recent advances in understanding their biogenesis and uptake, and their diagnostic and prognostic potential. By highlighting the role of sEVs in sepsis, we aim to underscore their promise in improving early detection, guiding therapeutic decisions, and advancing personalized medicine.
Year:
2025
Background Elevated cefepime blood concentrations can cause neurotoxicity in adults. The consequences of elevated cefepime concentrations among pediatric patients are unknown. Future exploration of such effects requires first identifying patients at risk for elevated cefepime exposure. We investigated the role of acute kidney injury as a risk factor for increased cefepime concentrations in critically ill children. Methods This was a retrospective analysis at a single pediatric intensive care unit. Analyzed patients received at least 24 h of cefepime and had at least two opportunistic samples collected for total cefepime concentration measurement. Individual pharmacokinetic (PK) profiles during treatment courses were reconstructed using Bayesian estimation with an established population PK model. Elevated trough concentration ( C min ) was defined as ≥ 30 mg/L based on adult toxicity studies. The effect of kidney dysfunction on cefepime PK profiles was interrogated using a mixed-effect model. Results Eighty-seven patients were included, of which 13 (14.9%) had at least one estimated C min ≥ 30 mg/L. Patients with elevated C min were more likely to have acute kidney injury (AKI) during their critical illness (92% vs. 57%, p = 0.015 for any AKI; 62% vs. 26%, p = 0.019 for severe AKI). Patients who had AKI during critical illness had significantly higher cefepime exposure, as quantified by the area under the concentration–time curve over 24 h (AUC 24h ) and C min . Conclusions Among critically ill children, AKI is associated with elevated cefepime concentrations. Identifying these high-risk patients is the first step toward evaluating the clinical consequences of such exposures. Graphical abstract
Year:
2025
Year:
2025
Background Pediatric sepsis is a leading cause of global mortality, particularly among children, with limited therapeutic options beyond antibiotics and organ support. The Pediatric Sepsis Biomarker Risk Model (PERSEVERE-II) stratifies mortality risk in pediatric septic shock, yet the molecular mechanisms underlying high mortality risk remain incompletely understood. Methods We analyzed whole blood transcriptomes collected from 81 children with septic shock on day 1 of meeting study criteria. Patients were stratified into high- and low-mortality risk groups according to the PERSEVERE-II biomarker risk model. Using weighted gene co-expression network analysis (WGCNA) and differential gene expression analyses, we identified molecular pathways and transcription factors (TFs) associated with mortality risk. Cell type differences were inferred using CIBERSORTx and using a reference single-cell dataset inclusive of neutrophils and their subsets. Findings We identified distinct molecular profiles with high-risk patients displaying significant overexpression of genes related to neutrophil degranulation and innate immunity, alongside suppressed adaptive immune responses. The predominance of developing neutrophils underscored a major role of emergency granulopoiesis. Key TFs identified, including LTF , FOXM1 , KLF1 , and CEBPB , were linked to high-risk gene expression signatures. Our findings indicate a pathological shift toward a dysregulated neutrophil-driven hyperinflammation and adaptive immune suppressive state, which together are associated with adverse outcomes. Interpretation Our results suggest that neutrophil dysregulation underpins the high mortality risk conferred by the PERSEVERE-II model. The identified transcriptional regulators may provide potential targets to mitigate neutrophil dysregulation and improve outcomes among high-risk patients.
Year:
2025
There has been growing interest in precision dosing of beta‐lactam antibiotics in recent years. At our institution, a quaternary children's hospital, we launched a new PK consult service utilizing a model‐informed precision dosing (MIPD) approach to provide personalized dosing recommendations for cefepime. This consult service leveraged the infrastructure of an existing PK consult service at our institution for other drugs, such as immunosuppressants. In this manuscript, we describe the challenges in the development of a beta‐lactam PK consult service due to fundamental differences between the new service and the existing PK consult service, such as varying levels of evidence for target goals for beta‐lactam antibiotics versus immunosuppressants, and how they were addressed. We then present the workflow and infrastructure of our beta‐lactam PK consult service to provide guidance for other institutions who may be interested in launching a similar service. Lessons learned throughout the process of building the service, including the importance of engaging multiple, diverse stakeholders early on and starting with one drug at a time, are provided.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (10)
Tomoyuki Mizuno
Cincinnati Children's Hospital Medical Center
Steven Miller
Department Head
The University of British Columbia
Cynthia Bearer
Chief, Division of Neonatology; William & Lois Briggs Chair of Neonatology
Case Western Reserve University
Zachary Taylor
Assistant Professor
Cincinnati Children's Hospital Medical Center
Basilia Zingarelli
Professor/Director of Basic Science Research
Cincinnati Children's Hospital Medical Center
Sonya C. Tang Girdwood
-
Takahisa Nakamura
Associate Professor
Cincinnati Children's Hospital Medical Center
Stephen Standage
Clinical Associate Professor
University of Cincinnati
Mihir Atreya
Research Assistant Professor
Cincinnati Children's Hospital Medical Center
Andrew Lautz
Research Associate Professor
Cincinnati Children's Hospital Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.